- Trials with a EudraCT protocol (212)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
212 result(s) found for: Binding protein.
Displaying page 6 of 11.
EudraCT Number: 2004-000535-29 | Sponsor Protocol Number: 24981 | Start Date*: 2004-09-29 | |||||||||||
Sponsor Name:Serono International S.A. | |||||||||||||
Full Title: A multicentre, open label and subsequent randomised, double blind, placebo controlled phase III study to assess the safety and efficacy of maintenance and extended therapy with subcutaneously admin... | |||||||||||||
Medical condition: Psoriasis is an inflammatory skin disorder that affects between 1 and 2% of the population. It is characterised by an increased proliferation of the epidermis, and presents as well-defined thickene... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) IT (Prematurely Ended) DK (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000375-42 | Sponsor Protocol Number: S339.2.001 | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals GmbH | |||||||||||||
Full Title: A multi-center, double-blind, parallel-design, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of oral recombinant microbial lipase (SLV339) in subjects with pa... | |||||||||||||
Medical condition: Pancreatic exocrine insufficiency due to chronic pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) SE (Prematurely Ended) HU (Prematurely Ended) CZ (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004024-11 | Sponsor Protocol Number: SHP648-101 | Start Date*: 2020-05-04 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects | |||||||||||||
Medical condition: Hemophilia B is a X-linked recessive bleeding disorder caused by mutations in the gene encoding clotting factor IX (FIX) that result in disruption of the normal clotting pathway. Hemophilia B affec... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002584-63 | Sponsor Protocol Number: VAC31518COV2001 | Start Date*: 2020-09-02 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults ... | |||||||||||||
Medical condition: Healthy Volunteers (Prevention of COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Restarted) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003643-29 | Sponsor Protocol Number: VAC31518COV3009 | Start Date*: 2020-11-10 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older E... | |||||||||||||
Medical condition: Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) ES (Temporarily Halted) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003866-96 | Sponsor Protocol Number: BEMI-2015 | Start Date*: 2016-04-29 | |||||||||||
Sponsor Name:ANGELA PUENTE | |||||||||||||
Full Title: Randomized controlled trial on the safety and efficacy of low molecular weight heparins in the prevention of thrombotic events in hospitalized cirrhotic patients | |||||||||||||
Medical condition: Prevention of thrombosis in cirrhotic patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018590-38 | Sponsor Protocol Number: 70421 | Start Date*: 2010-04-14 | |||||||||||
Sponsor Name:LUMC | |||||||||||||
Full Title: The thrombogenicity of the dienogest/estradiol valerate containing oral contraceptive (Qlaira) | |||||||||||||
Medical condition: We will investigate the thrombogenicity of two different oral contraceptives: dienogest/estradiol valerate (Qlaira) in comparison to levonorgestrel/ethinylestradiol (Microgynon-30) used by healthy ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000975-21 | Sponsor Protocol Number: RET-AFLI-2014-01 | Start Date*: 2014-06-16 |
Sponsor Name:Fundación Retinaplus + | ||
Full Title: A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. ... | ||
Medical condition: Macular edema secondary to central retinal vein occlusion. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000848-26 | Sponsor Protocol Number: BMF-AFLI-2013-01 | Start Date*: 2013-07-04 |
Sponsor Name:Barcelona Macula Foundation | ||
Full Title: Phase IV study to evaluate the efficacy of aflibercept in subjects with neovascular age-related macular degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of ... | ||
Medical condition: Wet age-related macular degeneration | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003311-32 | Sponsor Protocol Number: F 0106 | Start Date*: 2008-02-01 |
Sponsor Name:FORIM GmbH | ||
Full Title: Comparative surveillance study to assess the effect of lipid based nutrition vs. standard regimen on clinical outcome in ventilated patients. | ||
Medical condition: The aim of the presented surveillance is to confirm the results of the pilot study showing a significant reduction in respirator days and ICU-stay in patients with lipid based nutrition compared to... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004272-11 | Sponsor Protocol Number: 2B | Start Date*: 2011-11-30 |
Sponsor Name:Erasmus MC | ||
Full Title: The BOKITO-2B Study: Tenofovir DF Bone and Kidney Toxicity. Incidence and reversibility in HBV-monoinfected patients. | ||
Medical condition: Chronic hepatitis B | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000300-10 | Sponsor Protocol Number: IDI-AFLI-2013-01 | Start Date*: 2014-04-23 |
Sponsor Name:Fundació Instituto de Investigación Biomédica de Bellvitge (Fundació IDIBELL) | ||
Full Title: Phase IV study to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation (RAP) lesions on an individualized ?Treat and Extend? (TAE) regimen. AFLIRAP Study. | ||
Medical condition: Retinal angiomatous proliferation lesions (RAP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004834-26 | Sponsor Protocol Number: 2017-12 | Start Date*: 2018-09-05 | |||||||||||
Sponsor Name:Albert Schweitzer hospital | |||||||||||||
Full Title: Influence of dose interval on the pharmacokinetics of both unbound and total fractions of clozapine and norclozapine in psychiatric patients in the Netherlands | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001569-16 | Sponsor Protocol Number: VITPED/P01/04/MU.UK | Start Date*: 2006-07-17 |
Sponsor Name:BAXTER SAS R&D Parenteral Nutrition | ||
Full Title: EFFICIENCY AND SAFETY OF CLINAVIT PAEDIATRIC AT A WEIGHT DEPENDANT DOSE ADMINISTERED DAILY FOR 5 CONTINUOUS DAYS ON 4 VITAMINS BLOOD LEVEL IN NEONATES AND CHILDREN UP TO 11 YEARS OF AGE RECEIVING P... | ||
Medical condition: No special medical condition but Patient requiring for any underlying pathology at least 5 days of total parenteral nutrition, representing at least 90% of their total energy needs | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001428-38 | Sponsor Protocol Number: RRK2939 | Start Date*: 2006-09-18 |
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | ||
Full Title: Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy | ||
Medical condition: Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-C... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003297-13 | Sponsor Protocol Number: D5892N00005 | Start Date*: 2005-12-01 |
Sponsor Name:Imperial College | ||
Full Title: A randomised, double-blind, placebo-controlled, parallel-group study to investigate the effect of Symbicort® and Pulmicort® on HAT and HDAC expression and activity in induced sputum cells obtained ... | ||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-002124-17 | Sponsor Protocol Number: IMO-AFLI-2013-01 | Start Date*: 2013-10-04 |
Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular | ||
Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD). | ||
Medical condition: Wet age-related macular degeneration | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005874-24 | Sponsor Protocol Number: PEI004/2021 | Start Date*: 2022-07-01 |
Sponsor Name:Juan Enrique Domínguez Muñoz | ||
Full Title: Open label randomized, multicentre, controlled trial of pancreatic enzyme replacement therapy (PERT) for pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer | ||
Medical condition: pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-007170-30 | Sponsor Protocol Number: TUD-Psslan-031 | Start Date*: 2008-06-03 |
Sponsor Name:Technical University of Dresden, faculty of medicine | ||
Full Title: Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten Investigation of phenotype and f... | ||
Medical condition: Psoriasis vulgaris | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2018-003199-10 | Sponsor Protocol Number: OLE-NLRC4/XIAP.2016.001 | Start Date*: Information not available in EudraCT |
Sponsor Name:AB2 Bio Ltd. | ||
Full Title: Open-label extension study with Tadekinig alfa (r-hIL-18BP) to monitor safety and tolerability in patients with IL-18 driven monogenic autoinflammatory conditions: NLRC4 mutation and XIAP deficiency | ||
Medical condition: NLRC4 mutation XIAP deficiency | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
